phrykt

Imunon, Inc. (IMNN): who owns it and who trades it

As of Nov 16, 2026, IMNN insiders reported 6 open-market sales worth $38.1K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Susan Eylward (General Counsel and Corp), with $38.1K.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, IMNN insiders reported $0 of open-market purchases and $38.1K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$38.1K
6 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 31, 2026
Filed Sep 1, 2026

Purchases and sales by month

$20.6K$20.6KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 31, 2026Susan EylwardGeneral Counsel and CorpSale2,525$1.56$3.9KForm 4
Aug 17, 2026Susan EylwardGeneral Counsel and CorpSale2,449$1.63$4KForm 4
Aug 3, 2026Susan EylwardGeneral Counsel and CorpSale2,541$1.57$4KForm 4
Jul 20, 2026Susan EylwardGeneral Counsel and CorpSale2,150$1.78$3.8KForm 4
Jul 6, 2026Susan EylwardGeneral Counsel and CorpSale920$1.88$1.7KForm 4
Jun 29, 2026Susan EylwardGeneral Counsel and CorpSale11,800$1.75$20.6KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Susan EylwardGeneral Counsel and Corp Sec–$38.1KAug 31, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IMNN short interest

Low short interest. 3.8% of IMNN shares are sold short: about 1 share in 26. Over the last 12 reports the number of shares short went up 47%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 215,645 IMNN shares were sold short, 3.8% of the shares outstanding, up 245.8% from the report before. At the average daily volume of 144,672 shares, buying them all back would take about 1.5 trading days (days to cover).

Shares short, % of all shares

3.84%May 15Oct 304.35%

Days to cover

1.5May 15Oct 304.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026215,6453.84%+246%144,6721.5
Oct 15, 202662,3661.11%-64%92,7801.0
Sep 30, 2026173,1973.09%-11%142,3531.2
Sep 15, 2026193,6393.45%+114%154,0791.3
Aug 31, 202690,3831.61%-20%64,9811.4
Aug 14, 2026112,9582.01%-25%44,6682.5
Jul 31, 2026150,2033.83%+717%395,2911.0
Jul 15, 202618,3950.47%-64%31,4221.0
Jun 30, 202650,9691.30%-34%94,3431.0
Jun 15, 202677,0341.96%+34%49,6821.6
May 29, 202657,6171.47%-61%64,0551.0
May 15, 2026146,8603.74%-6%41,0383.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Imunon company events

Imunon filed 15 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership). The latest was on Oct 27, 2026.

  1. Oct 27, 2026AnnouncementImunon, Inc. made available an investor presentation, which the Company expects to use in connection with investor calls and/or conferences. Filing
  2. Oct 21, 2026AgreementImunon, Inc. entered into an Asset Purchase Agreement with VoxelDox Therapeutics, Inc., pursuant to which the Company agreed to sell to VoxelDox the Company’s assets relating to ThermoDox®, a heat-activated liposomal formulation of doxorubicin, including related trademarks, regulatory filings… Filing
  3. Sep 29, 2026AgreementAs previously reported, on June 2, 2026, Imunon, Inc. entered into a securities purchase agreement with Streeterville Capital, LLC, providing for the issuance and sale by the Company, and the purchase by the Investor, of (i) 250 shares of the Company’s Series A Preferred Stock, par value $0.01 per… Filing
  4. Aug 11, 2026LeadershipThe Compensation Committee and the Board of Directors of Imunon, Inc., as applicable, approved compensatory programs for certain executive officers, pursuant to which such executive officers may elect to receive a percentage of their base salary in the form of shares of common stock and will… Filing
  5. Aug 11, 2026ResultsReleased financial results. Filing
  6. Jun 30, 2026LeadershipJeffrey Church informed Imunon, Inc. of his intent to retire from the position of interim Chief Financial Officer (a position he has held since January of 2026), effective July 1, 2026. Filing
  7. Jun 16, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Imunon, Inc. held on June 16, 2026, the Company’s stockholders approved an amendment to the IMUNON, Inc. 2018 Stock Incentive Plan, which amendment was approved by the Company’s board of directors on February 27, 2026. Filing
  8. Jun 4, 2026AgreementImunon, Inc. entered into a securities purchase agreement with Streeterville Capital, LLC, providing for the issuance and sale by the Company, and the purchase by the Investor, of (i) 250 shares of the Company’s Series A Preferred Stock, par value $0.01 per share, at a price of $10,000 per share… Filing
  9. May 12, 2026ResultsReleased financial results. Filing
  10. May 4, 2026LeadershipCompensatory Arrangements of Certain Officers. Filing
  11. Mar 31, 2026ResultsReleased financial results. Filing
  12. Mar 23, 2026AnnouncementImunon, Inc. filed a prospectus supplement to register an additional $7 million of shares of the Company’s common stock, par value $0.01 per share, issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement… Filing
  13. Feb 5, 2026LeadershipKhursheed Anwer informed Imunon, Inc. of his intent to retire as Executive Vice President and Chief Scientific Officer from the Company, and Dr. Anwer’s employment with the Company will end, effective February 20, 2026. Filing
  14. Jan 7, 2026LeadershipImunon, Inc. announced that Kimberly Graper, its interim Chief Financial Officer, will be resigning from her role effective January 14, 2026. Filing
  15. Dec 31, 2025AgreementImunon, Inc., a Delaware corporation, entered into a Securities Purchase Agreement with a single healthcare-focused institutional investor for a registered direct offering of (i) 330,000 shares of its common stock, par value $0.01 per share, (ii) pre-funded warrants in lieu of Shares, to the extent… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Imunon financials

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IMNN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G/A5.0%
Nov 16, 2026Armistice Capital, LLC13G/A5.0%

Questions about Imunon, Inc. (IMNN) stock

Are IMNN insiders buying or selling?

In the last 12 months, IMNN insiders reported no open-market purchases and 6 sales worth $38.1K. The latest trade was on Aug 31, 2026. See every trade.

What is the short interest in IMNN?

As of Oct 30, 2026, 215,645 IMNN shares were sold short, 3.8% of the shares outstanding, up 245.8% from the report before. At the average daily volume of 144,672 shares, buying them all back would take about 1.5 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.